Summary Glutathione S-transferase sub-types a, 1t and were assessed by immunocytochemistry in 109 biopsies of ovarian tissue, comprising malignant epithelial tissue in 86 cases and tissue of ovarian origin considered to be normal in 23. Glutathione S-transferase n was the most prevalent, being present in all except one malignant epithelium studied and 83% of non-malignant tissue. There were no significant differences in the overall distribution of positive staining for a, and in the malignant and non-malignant biopsies, although the intensity of staining was greater in the malignant epithelium. Stromal staining was in general more pronounced in the malignant biopsies, and this was particularly prominent in the case of the a sub-type. Positive staining was seen more frequently in the less well-differentiated tumours, and a diffuse cytoplasmic pattern was the most common observation in tumours of moderate and poor differentiation. There was no significant association between survival and the presence or absence of sub-type staining of a and sub-type. For the sub-type at, patient survival was found to correlate with the intensity of staining (on a 0-+ + + scale). Those patients showing resistance to cytotoxic chemotherapy were found to have a higher intensity of staining for GSTi than responding patients.
Immunocytochemistry has made a great contribution to the improved classification of human tumours, both in terms of histogenesis and more recently in the related area of prediction of outcome. In breast and ovarian cancers localisation of the epidermal growth factor (EGF) receptor status and HER-2/neu oncogene product have been shown to correlate well with survival (Sainsbury, 1987; Haldane et al., 1990) . These factors are primarily thought to reflect differences in proliferation rates of the tumours, and are not directly related to the mechanism of action of any specific agent used in their treatment. Advances in treatment of these tumours have been impaired by the inability to predict with any degree of certainty which cases will respond to specific anticancer agents, or those which show a molecular phenotype which makes it likely they will be insensitive to a particular class of compounds.
There is increasing evidence that a group of proteins associated with intrinsic or acquired resistance may be related to response to anticancer chemotherapy. Of these, the p170 glycoprotein has now emerged as an independent predictive factor in tumours (Chan, 1990) , as well as being present in some normal tissues including liver, adrenal, kidney and colon (Fojo, 1987) , suggesting that it may also be a marker of intrinsic resistance.
However, resistance in human tumours is undoubtedly multifactorial, and several other mechanisms, including alterations in glutathione associated enzymes and DNA repair mechanisms may co-exist.
It has been shown that preneoplastic hepatocytes are more resistant than normal surrounding hepatocytes to chemical necrosis on account of their lower capacity to activate xenobiotics on the one hand, and their higher detoxifying capacity on the other (Farber & Sarma, 1987 ). The precise way in which the relative differences in phenotype between normal and neoplastic cells is related to the genetic instability of the malignant clones is as yet not clear.
The glutathione S-transferases are a family of proteins, comprising three main classes a, 1t and x, which are known to have several major functions among which are the detoxification of xenobiotics (Pickett, 1989) . They may play an important role in the initial defence of the body against potential carcinogens in sites such as the gastrointestinal tract and liver by acting either as intercellular binding proteins or by conjugation with glutathione (Sato, 1988) . Dulik et al. (1986) have shown that melphalan may be inactivated by the latter mechanism. They are ubiquitous throughout the tissues of the body, but there is considerable variation in sub-type distribution between organs (Harrison, 1990) . The n class glutathione S-transferases are the most prevalent in human tumours, and transfection experiments in yeast have demonstrated they confer resistance to doxorubicin and chlorambucil (Black et al., 1990) . There is also evidence that a class glutathione S-transferase has a particular role in the cellular resistance to the alkylating agents melphalan and chlorambucil (Lewis et al., 1988; Tew et al., 1990) , while nitrosourea detoxification may be carried out by the 1t class enzymes (Smith et al., 1989) .
There is, however, a lack of clinical studies on which to validate these in vitro data, which The majority of the malignant cases (n = 73) were treated on protocols comprising either oral chlorambucil (n = 6), single agent cisplatin (n = 4) or a combination of cisplatin 80 mg m 2 and cyclophosphamide 800 mg m-2 (n = 63) for up to six cycles. The cases of non-malignant ovarian tissue were obtained either from tissue adjacent to the malignant biopsies or by searching the files of Arrowe Park Hospital Pathology Department. Survival was calculated by the method of Kaplan-Meier, and differences between the curves analysed by the log-rank method (Peto, 1977) .
Results
The distribution of positive staining fcr each sub-type is shown in Table I for the 86 malignant biopsies, and Table II for the 23 non-malignant biopsies. GSTi was present in all but one of the malignant biopsies in the epithelium, and staining was more intense than with a and ti which were present in 59% and 71% respectively of these biopsies. Illustrations of the positive epithelial staining in the malignant cases are represented in Figure 1 . This epithelial staining was not found to be related to differentiation. In the stroma, staining was of much lower intensity than seen in the epithelium, except in the case of GSTa where strong cytoplasmic staining was noticed in discrete cells in the stroma (illustrated in Figure la and 
Discussion
This immunocytochemical study has demonstrated the relative predominance of GSTi in both distribution and intensity in malignant ovarian epithelial tissue, compared to GSTa and ft. Staining of the stroma in general mirrored that of the epithelium, but was of much lower intensity. The exception to this was the stromal staining for a, where foci of + + and + + + staining cells were noted. The identity of these cells is not clear at present, and they did not seem to have prognostic significance.
There was no obvious difference in the staining between the non-malignant and malignant epithelium, or between the stroma and staining in these categories. The non-malignant cases comprised a heterogeneous group of conditions with a relative predominance of dense fibrous stroma compared to epithelium and a variable proportion of necrotic tissue, and it is possible that some of the observed stromal staining, which was seldom very intense, could be artefactual. The dense GSTa positive stromal cells were not observed in the nonmalignant cases. The principal observations made in this series were firstly the clear relationship between GSTn intensity and survival, prognosis being poorer with greater intensity of GSTi staining. The effect appeared to be independent of differentiation, and was not related to other clinical risk factors. Secondly, a high proportion of anticancer drug resistant patients showed intense GSTi staining. Taken together these observations provide evidence that GSTn expression has prognostic significance in human tumours, and lend further support for the role of GSTic in drug resistance. However, these studies need to be reinforced by those using alternative methods of analysis (e.g. Western blotting) to quantify the isoenzymes.
The relationship between response to drug treatment and survival is a complex one, as both may be sensitive to a number of variables. The effect of proliferation rate, or differentiation may be paradoxical in that less well differentiated tumours may respond better to anticancer therapy, but may also have a poor prognosis, as is well recognised in non-Hodgkin's lymphomas, and in certain solid tumours including ovarian cancer. A complete response in general is the most predictive of prolonged survival but the numbers in the individual subgroups of response and GSTIt staining intensity are small in this study. Both are continuous variables and have been amalgamated into groups for analysis. In the malignant biopsies the strongest weight has been given to the + + and + + + categories, which are defined with reference to the positive control tissue, as normal tissues contain significant quantities of glutathione Stransferases.
Previous studies of GST enzyme expression have only rarely found a correlation with clinical outcome, but Holmes et al. (1990) showed that GST7 expression was related to outcome in leukaemia. In a recent study van der Zee et al. (1992) found no correlation between the level of GSTc and response to cisplatin/cyclophosphamide chemotherapy. These authors found a reduction in GSTic biopsies taken after chemotherapy compared to pre-treatment levels, whereas Murphy et al. (1992) found no differences in GST activity between 33 pre-chemotherapy and 20 post-chemotherapy tumours using an enzyme assay which does not distinguish between the sub-types.
In cell lines (Cowan et al., 1986) , as well as solid tumours (Keith et al., 1990) investigators have sought a correlation between GSTi expression and the multi-drug resistance phenotype (MDR 1 expression) on the assumption of coregulation of resistance mechanisms. The drugs used in the present study comprised either alkylating agents or cisplatinum, and hence MDR-1 expression would be expected to be less important than other mechanisms such as glutathione transferase mediated detoxification, which has been well-characterised as an important mechanism of alkylating agent resistance (Teicher & Frei, 1991) . Increased GST expression has been found in rat and Chinese ovary cells resistant to chlorambucil, rat glioma cells resistant to nitrogen mustard and human cells resistant to cisplatinum (Wang & Tew, 1985; Lewis et al., 1988; Evans et al., 1987; Teicher et al., 1987) . The role of the individual sub-types of GST in relation to resistance to anticancer agents has still not been resolved although GSTx has been the most frequently studied (Tew et al., 1990) . It has been shown that GSTy class have the highest activity in the detoxication of nitrosoureas in the rat (Smith et al., 1989) . In the yeast S. cerevisiae transfection of a and x GST has been shown to give rise to increased resistance to doxorubicin and chlorambucil (Black et al., 1990 ) and transfection of GSTI into NIH 3T3 cells provided a degree of protection against doxorubicin, but not against alkylating agents or cisplatinum (Nakagawa et al., 1990) . However, in human breast cancer cells, Moscow et al. (1989) found that transfection of GSTi produced no increased resistance to chlorambucil, melphalan, or doxorubicin.
The GSTir sub-type has been shown to be 2-5 fold overexpressed in neoplastic compared to normal tissues in human breast and ovarian tissues (Buser et al., 1991) . This enzyme has been shown to be capable of catalysing conjugation of glutathione with electrophiles including cytotoxic drugs (Dulik et al., 1986) . It is the most ubiquitous of the GST sub-types, and is known to be inducible in response to a number of extracellular stimuli, and show increased expression during malignant transformation (Sato, 1988) . It is therefore possible that the level of GSTi expression contributes to the intrinsic resistance of ovarian tumours, by a process that is related to the mechanism of malignant transformation. The glutathione transferases are subject to transcriptional regulation, and are known to be important in detoxification of chemical carcinogens (Mannervik, 1985) and hence their overexpression may also be an important facet of acquired cytotoxic drug resistance. This study has shown there is a relationship between qualitative measurement of GSTi and category of response to anticancer drugs in ovarian cancer tissues.
